Ironwood Pharmaceuticals CEO Mark Mallon receives $10M in 2019
Ironwood Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 21, 2020
Ironwood Pharmaceuticals reported fiscal year 2019 executive compensation information on April 21, 2020.
In 2019, six executives at Ironwood Pharmaceuticals received on average a compensation package of $5.4M, a 82% increase compared to previous year.
Average pay of disclosed executives at Ironwood Pharmaceuticals
Mark Mallon, Chief Executive Officer, received $10M in total. 38% of Mallon's compensation, or $3.8M, was in option awards. Mallon also received $880K in bonus, $797K in non-equity incentive plan, $750K in salary, $3.7M in stock awards, as well as $145K in other compensation.
For fiscal year 2019, the median employee pay was $202,151 at Ironwood Pharmaceuticals. Therefore, the ratio of Mark Mallon's pay to the median employee pay was 50 to one.
Peter M. Hecht, Chief Executive Officer, received a compensation package of $6.2M, which increased by 19% compared to previous year. 99% of the compensation package, or $6.1M, was in option awards.
Thomas A. McCourt, President, earned $5.1M in 2019, a 137% increase compared to previous year.
Mark G. Currie, Chief Scientific Officer, received $4.1M in 2019, which increases by 69% compared to 2018.
Gina Consylman, Chief Financial Officer, earned $3.5M in 2019, a 80% increase compared to previous year.
Halley E. Gilbert, Chief Administrative Officer, received $3.4M in 2019, which increases by 78% compared to 2018.
Related executives
Mark Mallon
Ironwood Pharmaceuticals
Chief Executive Officer
Gina Consylman
Ironwood Pharmaceuticals
Chief Financial Officer
Halley Gilbert
Ironwood Pharmaceuticals
Chief Administrative Officer
Thomas McCourt
Ironwood Pharmaceuticals
Chief Executive Officer
Peter Hecht
Ironwood Pharmaceuticals
Chief Executive Officer
Mark Currie
Ironwood Pharmaceuticals
Chief Scientific Officer
You may also like
Source: SEC filing on April 21, 2020.